summit – Talk Bio

Actionable Insights Powered by AI

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

2 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, Clinical Trials, Ivonescimab, PD-1/VEGF, Pfizer, Solid Neoplasm, summit

Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials

Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

8 months ago talkbio0Tagged Akeso, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-L1, pembrolizumab, Phase 3 trial, Positive, summit

Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

11 months ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

11 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.